Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Japan As Represented by President of National Cancer Center

Other

Nihon University

Kyowa Medex Co., Ltd.

Tokai University

Kyowa Kirin Co., Ltd.

Akiko Furuya

Nobuo Hanai

Kazuyasu Nakamura

Kenya Shitara

Motoo Yamasaki

Kenji Shibata

Hiroshi Ando

Hideharu Anazawa

Rinpei Niwa

Yuka Sasaki

Mikiko Sakurada

Mitsuo Satoh

Masamichi Koike

Toshio Ota

Kazuhiro Masuda

Akihiro Iida

Eisuke Mekada

Shingo Miyamoto

Kiyoshi Takatsu

Kumiko Takahashi

Emi Shoji

Ryo Iwamoto

Yuki Kobayashi

Atsushi Ochiai

Susumu Sekine

Kazuya Yamano

Tsuguo Kubota

Yuji Ohki

Norihiko Shiraishi

Sumio Sugano

Akira Tanaka

Miho Takebayashi

Yusuke Nakamura

Emi Hosaka

Hajime Yoshida

Masayo Suzuki

Hiroe Toki

Takeshi Takahashi

Yutaka Kanda

Satoshi Nakagawa

Tatsunari Nishi

Masami Okabe

Tetsuro Kuga

So Ohta

Hiroyuki Ishida

Seiji Sugimoto

Yoko Kato

Takashi Kuwabara

Satoshi Kobayashi

Tetsuyoshi Ishiwata

Ayako Kawabata

Shigemasa Sawada

Masami Takei

Katsuhiro Mori

Naoko Hiura

Naoya Kimoto

Hidenao Sato

Naoki Shimada

Maiko Hirota

Susume Sekine

Toshiaki Kamei

Toshiaki Saeki

Chie Ito

Noboru Taniguchi

Akira Kusano

Kyosuke Nagata

Kaoru Miyamoto

Osamu Mikuni

Hiroaki Kohno

Takashi Sato

Tomomitsu Hotta

Kiyoshi Ando

The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.

Anti-CD27 antibody

An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as 'ASCT2') or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.

DNA encoding an anti-system ASC amino acid transporter 2 (ASCT2) antibody

The present invention provides a method for screening a patient to be administered with a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient, said method comprising collecting samples from patients who expresses an antigen which is recognized by the anti-cancer antibody, measuring cadherin function in the samples, and selecting a patient whose the cadherin function is decreased or deleted; a method for screening a patient who has a high efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient; and a method for improving an efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient.

Method for screening of patient to be administered with pharmaceutical agent comprising anti-cancer antibody as active ingredient

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

Method for producing recombinant antibody and antibody fragment thereof

Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.

Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor

Anti-system ASC amino acid transporter 2 (ASCT2) antibody

Method for treating the Th2-mediated disease

An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene.

Anti-PERP recombinant antibody

The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP.

Anti-perp antibody

Using the proteins of the present invention, DNAs encoding the proteins, and antibodies recognizing the proteins, detection methods for diseases relating to the novel insulin-like growth factor binding proteins of the present invention, as well as diagnostic agents, preventive agents, and therapeutic agents for diseases relating to the proteins of the present invention can be provided.

Antibodies to insulin-like growth factor binding protein and uses thereof

Method for treating Th2-mediated disease

The present invention relates to a method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases, a method of discriminating leukemia from pre-leukemia or aleukemic malignant blood diseases, a method of discriminating aplastic anemia from myelodysplastic syndrome, a method of diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells, and a method of diagnosing the graft versus host disease, each of said methods comprising quantifying stem cell growth factor (SCGF). The present invention also makes it possible to provide an agent for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases and an agent for diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells or an agent for diagnosing graft versus host disease (GVHD), each containing as an active ingredient an antibody reacting with stem cell growth factor (SCGF).

Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor

Growing community of inventors

Tokyo, Japan

Akiko Furuya